Comparative Benchmarking
In the context of the broader market, INDP competes directly with industry leaders such as PCSA and DRMA. With a market capitalization of $4.63M, it holds a significant position in the sector. When comparing efficiency, INDP's gross margin of N/A stands against PCSA's N/A and DRMA's N/A. Such benchmarking helps identify whether Indaptus Therapeutics Inc is trading at a premium or discount relative to its financial performance.
